Repligen Co. (NASDAQ:RGEN) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. lessened its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 45.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,641 shares of the biotechnology company's stock after selling 21,120 shares during the period. Prudential Financial Inc.'s holdings in Repligen were worth $3,691,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of RGEN. Vanguard Group Inc. increased its holdings in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after acquiring an additional 56,723 shares during the period. Conestoga Capital Advisors LLC increased its position in Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after buying an additional 6,872 shares in the last quarter. DF Dent & Co. Inc. grew its stake in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after acquiring an additional 139,615 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Repligen by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock valued at $83,693,000 after acquiring an additional 14,398 shares in the last quarter. Finally, Stephens Investment Management Group LLC grew its position in Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after purchasing an additional 37,057 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Price Performance

NASDAQ:RGEN traded down $9.76 during trading hours on Friday, reaching $111.94. 1,826,070 shares of the company were exchanged, compared to its average volume of 686,321. The stock's 50-day moving average is $150.03 and its 200-day moving average is $147.62. Repligen Co. has a twelve month low of $106.78 and a twelve month high of $182.52. The firm has a market cap of $6.29 billion, a PE ratio of -219.49, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGEN has been the topic of a number of research analyst reports. TD Cowen initiated coverage on shares of Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. Canaccord Genuity Group raised their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Finally, StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Repligen presently has an average rating of "Moderate Buy" and a consensus price target of $178.64.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.